Quality-Adjusted Life Year

A quality-adjusted life year (QALY) is a standardized metric in health economics, clinical decision analysis, and public health policy that integrates both the quantity (duration) of human life and the health-related quality of life (HRQoL) into a single composite summary number. Originally formulated by Herbert E. Klarman (1968) in an economic evaluation of chronic renal failure treatment, axiomatized by G. W. Torrance, W. H. Thomas, and D. L. Sackett (1972), and popularized by Milton C. Weinstein and William B. Stason (1977) alongside British health economist Alan Williams (1985), the QALY weights each chronological year of life lived by a cardinal utility weight u anchored on an interval scale where u = 1.0 represents one year lived in full, perfect health and u = 0.0 represents death (with negative values u < 0.0 permitted for severe health states judged by respondents to be worse than death). Because QALYs provide a common, disease-agnostic denominator across disparate medical specialties—allowing analysts to compare the health gain of a pediatric vaccine against coronary artery bypass grafting, essential medicines for hypertension, or oncology immunotherapy—they serve as the primary outcome unit in cost-utility analysis (CUA) for national health technology assessment agencies worldwide.

Discrete Step-Function and Continuous Integral Equations

In its foundational discrete formulation, if an individual lives across K distinct consecutive health phases, spending duration t_k years in health state k characterized by constant quality-of-life utility weight u_k, the total undiscounted QALYs accumulated over that trajectory equal the sum of the time-weighted utilities:

QALY = ∑_k=1^K u_k × t_k

For example, living 4 years in perfect health (u = 1.0) yields 4.0 QALYs, which is mathematically equivalent to living 8 years in a chronic disabling health state valued at u = 0.50 (8 × 0.50 = 4.0 QALYs) or 5 years with moderate angina valued at u = 0.80 (5 × 0.80 = 4.0 QALYs).

In continuous-time survival modeling over a time horizon T, where S(t) represents the Kaplan-Meier or parametric probability of survival at time t after an intervention, u(t) represents the mean health-state utility of survivors at time t, and r represents the annual social discount rate (typically r = 0.03 or 3.0% per year in the United States and r = 0.035 or 3.5% in the United Kingdom), expected lifetime QALYs are given by the quality-adjusted survival integral:

E[QALY] = ∫₀^T S(t) · u(t) · e^−rt dt

When comparing a new medical intervention (Treatment A, such as a novel biologic or surgical procedure) against the current standard of care (Comparator B), the net health benefit ΔQALY is the area between the two quality-adjusted survival curves, which simultaneously captures gains from extending survival (ΔS(t) > 0) and gains from alleviating morbidity or disability (Δu(t) > 0) even when total lifespan is unchanged.

Health-state utility weights u ∈ [−0.59, 1.00] are measured using two distinct methodological frameworks: direct preference elicitation from individuals or general-population panels, and indirect multi-attribute utility instruments (MAUIs) equipped with pre-scored societal tariff matrices.

Why Societal vs. Patient Preferences Diverge

A crucial methodological choice in QALY construction is whether the utility weights u(h) should be elicited from patients currently living with the condition or from a representative sample of the general public (taxpayers/insurance pool members). Empirical studies consistently show that patients who have lived for years with paraplegia, blindness, colostomy, or hemodialysis assign substantially higher utility scores (e.g., u ≈ 0.70–0.85) to their own health state than the general public imagines (e.g., u ≈ 0.40–0.55), owing to psychological hedonic adaptation, assistive technology mastery, and response shift (recalibrating life goals around preserved capabilities). The U.S. Second Panel on Cost-Effectiveness in Health and Medicine and the UK National Institute for Health and Care Excellence (NICE) recommend general-population societal tariffs (such as EQ-5D) for macro-level resource allocation under universal health coverage, while examining patient-derived utilities in sensitivity analyses.

The Cost-Effectiveness Plane and Dominance

In health-economic evaluations, QALYs are paired with net direct medical and societal costs (C) to compute the Incremental Cost-Effectiveness Ratio (ICER), defined as the additional cost required to generate one additional QALY when adopting Intervention A over Comparator B:

ICER = (C_A − C_B) / (QALY_A − QALY_B) = ΔC / ΔQALY

When plotted on Black's Cost-Effectiveness Plane (with ΔQALY on the horizontal axis and ΔC on the vertical axis), four quadrants emerge:

1. Southeast Quadrant (ΔQALY > 0, ΔC < 0 — Dominant / Cost-Saving): The new intervention improves health outcomes while simultaneously reducing total healthcare expenditure (for example, childhood MMR vaccination, water chlorination, or smoking cessation pharmacotherapy). Dominant interventions are adopted unconditionally without needing an ICER threshold.
2. Northwest Quadrant (ΔQALY < 0, ΔC > 0 — Dominated): The intervention yields worse health outcomes at higher cost and is rejected unconditionally.
3. Northeast Quadrant (ΔQALY > 0, ΔC > 0 — Trade-Off Quadrant): Most novel pharmaceuticals, medical devices, and screening programs yield positive QALY gains (ΔQALY > 0) at a positive net cost (ΔC > 0). Here, an intervention is deemed cost-effective if its ICER falls below the health system's Willingness-to-Pay (WTP) threshold λ (ICER ≤ λ), or equivalently if its Net Monetary Benefit (NMB = λ · ΔQALY − ΔC) is positive (NMB > 0).
4. Southwest Quadrant (ΔQALY < 0, ΔC < 0): Disinvesting in a marginally effective technology saves resources that can be reallocated elsewhere if the cost saved per QALY foregone exceeds λ.

Across major health systems, benchmark ICER thresholds vary by macroeconomic capacity and health budget elasticity:

• United Kingdom (NICE): Standard threshold of £20,000 to £30,000 per QALY gained, with severity modifiers scaling up to £50,000/QALY for conditions causing severe absolute or proportional QALY shortfall, and up to £100,000–£300,000/QALY under the Highly Specialised Technologies program for ultra-rare monogenic disorders.
• United States (ICER / Academic Consensus): Typical benchmark range of $100,000 to $150,000 per QALY gained (with secondary sensitivity bounds at $50,000/QALY and $200,000/QALY).

Structural Comparison with Disability-Adjusted Life Years (DALYs)

While QALYs are the standard metric in high-income health technology assessment, global health agencies led by the World Health Organization (WHO) and the Institute for Health Metrics and Evaluation (IHME) utilize the Disability-Adjusted Life Year (DALY) (an extension of years of potential life lost):

• Polarity ("Health Gain" vs. "Health Gap"): A QALY is a positive measure of health gained (which policymakers seek to maximize), weighted by a utility weight u ∈ [0, 1] where 1.0 = perfect health and 0.0 = death. Conversely, a DALY (DALY = YLL + YLD) is a negative measure of disease burden / health lost (which policymakers seek to minimize), weighted by an inverted disability weight DW ∈ [0, 1] where 0.0 = perfect health and 1.0 = death (such that u ≈ 1 − DW).
• Reference Baseline: QALYs calculate survival multiplying observed cohort survival curves S(t) directly without referencing an external ideal life table, whereas DALYs measure premature mortality (YLL) as the gap against an aspirational global standard frontier life expectancy (e*₀ ≈ 86.6–89 years).

The "Double Jeopardy" Disability Critique and Equal Value of Life Years Gained (evLYG)

Philosophers and disability bioethicists—most notably John Harris (1987) and Erik Nord (1999)—identified an ethical tension in strict QALY maximization known as the Double Jeopardy or Baseline Disability Discrimination problem:

• Suppose Treatment X extends the life of a previously healthy adult (u = 1.0) by 10 years (generating 10 × 1.0 = 10.0 QALYs), whereas the exact same life-saving intervention extends the life of an individual with pre-existing paraplegia or cystic fibrosis (baseline utility u = 0.60) by 10 years, returning them to their baseline state (generating only 10 × 0.60 = 6.0 QALYs).
• Under a rigid utilitarian rule that solely maximizes total QALYs per dollar, life-extending treatments for populations with chronic permanent disabilities or advanced age appear 40% less cost-effective than identical life-extending treatments for fully able-bodied patients, conflicting with principles of health equity and the social determinants of health.

Because of this concern, the U.S. Patient Protection and Affordable Care Act (2010) and the Inflation Reduction Act (2022) prohibited the U.S. Centers for Medicare & Medicaid Services (CMS) from using traditional QALYs in ways that discount the value of extending the life of an individual on the basis of age, disability, or terminal illness. To preserve quantitative rigor while eliminating baseline disability discrimination during life extension, health economists developed two complementary corrective metrics now reported alongside traditional QALYs:

1. Equal Value of Life Years Gained (evLYG / evLY): Introduced by the U.S. Institute for Clinical and Economic Review (ICER), the evLYG incorporates quality-of-life improvements during shared survival time, but assigns an identical uniform weight of 0.851 (the general U.S. population mean health utility) to every additional year of life extended by a treatment, regardless of the patient's age, chronic illness, or permanent disability.
2. Health Years in Total (HYT): Formulated by Anirban Basu, Josh Carlson, and David Veenstra (2020), the HYT metric additively separates survival duration gains from quality-of-life utility improvements rather than multiplying them, ensuring that life-extending therapies for patients with baseline disabilities receive full credit for every year of survival added.

1. Weinstein, M. C., & Stason, W. B. (1977). "Foundations of cost-effectiveness analysis for health and medical practices." New England Journal of Medicine, 296(13), 716–721. https://doi.org/10.1056/NEJM197703312961304
2. Torrance, G. W. (1986). "Measurement of health state utilities for economic appraisal: a review." Journal of Health Economics, 5(1), 1–30. https://doi.org/10.1016/0167-6296(86)90020-290020-2)
3. Dolan, P. (1997). "Modeling valuations for EuroQol health states." Medical Care, 35(11), 1095–1108. https://doi.org/10.1097/00005650-199711000-00002
4. Whitehead, S. J., & Ali, S. (2010). "Health outcomes in economic evaluation: the QALY and utilities." British Medical Bulletin, 96(1), 5–21. https://doi.org/10.1093/bmb/ldq033
5. Sanders, G. D., Neumann, P. J., Basu, A., Brock, D. W., Feeny, D., Krahn, M., Kuntz, K. M., Meltzer, D. O., Owens, D. K., Prosser, L. A., Salomon, J. A., Sculpher, M. J., Trikalinos, T. A., Russell, L. B., Siegel, J. E., & Ganiats, T. G. (2016). "Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: Second Panel on Cost-Effectiveness in Health and Medicine." JAMA, 316(10), 1093–1103. https://doi.org/10.1001/jama.2016.12195